Latest developments and reimbursement policies for dabrafenib/dabrafenib medical insurance prices in 2025

Since its introduction into the Chinese market, Dabrafenib has achieved significant clinical application results in multiple fields. With the gradual promotion of this drug, it has been successfully included in China's medical insurance reimbursement system, especially in the treatment of advanced melanoma, non-small cell lung cancer (NSCLC), and thyroid cancer with BRAF V600E or V600K mutations, providing a more economical treatment option.

In the Chinese market, the original drug of dabrafenib is mainly available in 50 mg and 75 mg capsules. The common packaging is 120 capsules per bottle. The price varies according to the drug specifications and sales channels. Generally speaking, a 50 mg 120-capsule package may cost more than 10,000 yuan, while a 75 mg 120-capsule package may cost more than 10,000 yuan. For some patients, the high price of drugs remains an important consideration in their treatment decisions.

However, dabrafenib has been included in China's medical insurance reimbursement system and is usually classified as a Class B drug, which means that patients can enjoy a certain reimbursement ratio under the medical insurance policy. The specific reimbursement ratio is related to the region where the patient is located, the medical insurance policy, and the medical insurance cooperation of the hospital. In some big cities and key hospitals, after patients are reimbursed through medical insurance, their personal expenses may be reduced, which can ease the financial burden of treatment.

The price of dabrafenib in foreign markets is relatively low. For example, in the Turkish market, 75 mg of original medicine in a package of 120 pills is priced at about more than 7,000 yuan, which is quite different from the domestic price. However, factors such as exchange rate fluctuations and transportation costs may cause certain fluctuations in the actual purchase price. In addition, there are many generic drugs of dabrafenib in overseas markets. For example, the generic drugs produced in Laos have basically the same ingredients as the original drugs and cost about more than 2,000 yuan, which provides a more economical treatment option for some patients.

Reference materials:https://go.drugbank.com/drugs/DB08912